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Summary 
Introduction 
Health Problem 
Intracranial aneurysms (IA) are localised abnormal dilatations of the wall of 
brain arteries and are estimated to be prevalent in 3% of the adult population. 
Most IA are asymptomatic and have a low risk of rupture and thus a treat-
ment is not indicated. Larger aneurysms and IA located in the posterior cir-
culation present a higher risk of rupture and thus may warrant a preventive 
treatment. Current treatment options are microsurgical clipping and endo-
vascular coiling; however, these options are not satisfactory or even unfeasi-
ble for a subset of IA (e.g., wide-necked, fusiform or giant aneurysms), leav-
ing surgical parent vessel occlusion as a last resort. 
Description of Technology 
Flow diverters are tubular, braided metallic stents, that are deployed intra-
vascularly in the parent artery across the aneurysm neck using a microcathe-
ter approach. Through their dense mesh structure, they re-direct the blood 
flow leading to thrombosis and occlusion within the aneurysm sac. The stent 
is subsequently overgrown leading to reconstruction of the parent artery. As 
of 2008, several flow diverters have received marketing authorisation in Eu-
rope for the treatment of any intracranial aneurysms. In particular, however, 
flow diverters are claimed to allow occlusion of otherwise untreatable aneu-
rysms with parent vessel preservation. We, therefore, assessed the efficacy and 
safety of the treatment with flow diverters in two distinct populations: a) any 
unruptured IA that are indicated for preventive treatment and b) unruptured 
IA, that are indicated but not amenable for preventive treatment. 
 
Methods 
The EuNetHTA Core Model for Rapid Relative Effectiveness was the main 
source for selecting relevant assessment elements. We conducted a systemat-
ic literature search (without restriction on publication date) in bibliographic 
databases, in the Cochrane Library and in the database of the Centre for Re-
views and Dissemination, complemented by a SCOPUS hand search, to an-
swer the research questions in the domains effectiveness and safety. Selection 
of relevant documents (in English and German) was done by two persons in-
dependently. The Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) methodology was used for qualitatively summaris-
ing the results for the domains: “Safety” and “Clinical effectiveness”. 
Domain effectiveness 
For analysing the clinical effectiveness in population a) only randomised con-
trolled trials were included; in population b) also prospective uncontrolled 
studies with follow-up ≥6 months and ≥50 participants were included, pro-
vided that any of the defined outcomes were reported. The crucial outcomes 
to derive a recommendation were: overall mortality, disability/dependency, 
health-related quality of life, aneurysm retreatment rate and angiographic 
surrogate parameters (aneurysm occlusion and parent vessel stenosis). 
Hochrisiko-aneurysmen: 
Coiling oder Clipping als 
präventive Maßnahmen 
 
nicht möglich in einem 
Teil der IA 
Flow Diverter sind 
schlauchförmige 
Metallgeflechte 
 
Verschluss des IA  
durch Diversion des 
Blutflusses & 
Rekonstruktion des 
Ursprungsgefäßes 
Methode: basierend auf 
EuNetHTA Core Model; 
systematische 
Literatursuche in  
4 Datenbanken; GRADE 
Einschlusskriterien  
für Wirksamkeit 
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Domain safety 
For analysing the safety of the treatment with flow diverters, prospective con-
trolled and uncontrolled studies with follow-up ≥6 months were included. 
Uncontrolled studies were included only, if they either reported ≥200 partic-
ipants or ≥50 participants and reported mortality and further adverse events. 
The crucial outcomes to derive a recommendation were: neurological death, 
haemorrhage (total and early), ischemic stroke (total and early), new or wors-
ened disability/dependency. 
 
Results 
Available evidence 
Five prospective, multi-centre single-group studies were identified that ana-
lysed efficacy and safety of the treatment with flow diverters in unruptured 
intracranial aneurysms with varying definitions of “difficult to treat” (large, 
wide-necked, unfavourable dome-to-neck ration, fusiform, etc.). In total, re-
sults from 494 patients that were treated with flow diverters were reported. 
Clinical effectiveness 
Overall mortality ranged from 0 to 8%. Retreatment was reported in two stud-
ies in 0 and 4.5%. Angiography efficacy was in the range 49–85.7% after 6 
months and 81–86.6% after 1 year; however, parent artery stenosis ≥50% oc-
curred in 0 to 16.3%. Improved function was reported in two studies in 8.4% 
and 19.6%. No direct evidence on relative effectiveness of flow diverters in 
comparison to alternative treatment options was available. 
Safety 
After 6 months, neurological death was reported in 5 studies to occur in a 
range between 0 to 2.8%. Haemorrhage occurred in 0–6.2% of the participants, 
late haemorrhage (≥30 days) in a range of 0–2%. Ischemic stroke was report-
ed in the range of 0–3.7%. Worsened function was reported in a range of 2.7–
14% of the participants. No direct evidence on relative safety of flow divert-
ers in comparison to alternative treatment options was available. 
Upcoming evidence 
Five RCTs using flow diversion as an intervention are currently registered, 4 
of which target “difficult to treat” aneurysms with varying inclusion criteria 
(e.g., wide-necked or large). The FIAT trial is expected to provide efficacy 
and safety results of flow diversion versus standard treatment following the 
study completion date in April 2016. 
 
Discussion 
Flow diverters are claimed to provide a treatment option to otherwise untreat-
able aneurysms. In practice, however, there is no agreed definition of an “un-
treatable” aneurysm, as underlined by the heterogeneous inclusion criteria 
of the studies. In most patients, a standard treatment alternative likely exists 
and the trade-off of procedural risks with long-term beneficial outcomes will 
need to be established in RCTs. 
 
Einschlusskriterien  
für Sicherheit 
5 prospektive, 
multizentrische, 
unkontrollierte Studien 
Mortalität 0 bis 8 %; 
Aneurysmaverschluss 
49–85,7 % (6 mo) 
Nebenwirkungen:  
Tod, Hämorrhagie, 
Schlaganfall 
5 laufende RCTs 
keine klare Definition 
von „unbehandelbaren“ 
Aneurysmen  
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Conclusion 
There is moderate evidence for efficacy using the angiographic surrogate pa-
rameter aneurysm occlusion in a large percentage of treated aneurysms.  
The current evidence is, however, not sufficient to prove, that the assessed 
technology of endovascular embolization with flow diverters is more effec-
tive and safe with regards to clinical outcomes than no treatment, endovas-
cular coiling or surgical clipping.  
The re-evaluation is recommended in 2017, provided that data from random-
ised controlled trials will be available at that time. 
 
  
Surrogatparameter 
Aneurysmaverschluss: 
moderate Evidenz 
 
ungenügende Evidenz 
hinsichtlich klinischer 
Endpunkte im Vergleich 
zu Behandlungs-
alternativen 
 
 
Re-evaluierung 2017  
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Intrakranielle Aneurysmen (IA) sind lokalisierte abnorme Dilatationen der 
Wand der Hirnarterien. Sie treten mit einer geschätzten Prävalenz von 3 % 
der erwachsenen Bevölkerung auf. Die meisten IA sind asymptomatisch und 
weisen ein geringes Rupturrisiko auf: eine Behandlung ist somit nicht indi-
ziert. Größere Aneurysmen und IA der posterioren Zirkulation haben ein hö-
heres Rupturrisiko, das eine präventive Behandlung rechtfertigen kann. Ak-
tuelle Behandlungsmöglichkeiten sind das mikrochirurgische Clipping und 
das endovaskuläre Coiling ; diese Optionen sind jedoch für eine Teilmenge 
der IA (z. B. breithalsige IA oder Riesenaneurysmen) nicht zufriedenstellend 
oder sogar unmöglich durchzuführen, so dass der chirurgische Verschluss des 
Ursprungsgefäßes als letzte Option verbleibt. Flow Diverter versprechen hier 
eine minimalinvasive Alternative, die einen Aneurysmaverschluss bei Erhalt 
des Gefäßes ermöglicht. 
Beschreibung der Technologie 
Flow Diverter sind schlauchförmige Metallgeflechte, die endovaskulär über 
dem Aneurysmahals eingesetzt werden. Durch ihre dichte Netzstruktur len-
ken sie die Durchblutung um, was zu Thrombose und Verschluss des Aneu-
rysmasacks führt. Der Stent wird anschließend überwachsen, was die Re-
konstruktion der Stammarterie ermöglicht. Seit dem Jahr 2008 haben meh-
rere Flow Diverter die Zulassung in Europa für die Behandlung jedweder 
intrakranieller Aneurysmen erhalten. Insbesondere werden Flow Diverter 
jedoch für den Verschluss jener Aneurysma angeboten, für die es keine Be-
handlungsalternativen gibt. Wir haben deshalb die Wirksamkeit und Sicher-
heit der Behandlung mit Flow Divertern in zwei unterschiedlichen Patien-
tengruppen untersucht: a) alle unrupturierten IA, die für eine präventive Be-
handlung indiziert sind und b) unrupturierte IA, die zwar indiziert, aber für 
die Behandlung mit Coiling oder Clipping nicht zugänglich sind. 
 
Methoden 
Das EUnetHTA Core-Modell war die Hauptquelle für die Auswahl der je-
weiligen Bewertungselemente. Wir führten eine systematische Literaturre-
cherche in Literaturdatenbanken, in der Cochrane Library und in der Da-
tenbank des CRD, ergänzt durch eine SCOPUS Handsuche durch, um die 
Forschungsfragen in den Bereichen Wirksamkeit und Sicherheit zu beant-
worten. Die Auswahl der relevanten Studien (in Deutsch und Englisch) wur-
de von zwei Personen unabhängig voneinander durchgeführt. Die qualitati-
ve Zusammenfassung der Ergebnisse erfolgte nach der GRADE Methodik. 
Klinische Wirksamkeit 
Für die Analyse der klinischen Wirksamkeit in der primären Studienpopu-
lation a) wurden nur randomisierte kontrollierte Studien einbezogen; in der 
sekundären Studienpopulation b) wurden auch prospektive unkontrollierte 
Studien mit Follow-up ≥6 Monaten und ≥50 Teilnehmer eingeschlossen, vo-
rausgesetzt, dass sie die festgelegten Endpunkte behandelten. Die entschei-
denden Endpunkte, anhand derer eine Empfehlung abgeleitet wurde, sind: 
Hochrisiko-aneurysmen: 
Coiling oder Clipping als 
präventive Maßnahmen 
 
 
nicht möglich in einem 
Teil der IA 
Flow Diverter sind 
schlauchförmige 
Metallgeflechte 
 
Verschluss des IA  
durch Diversion des 
Blutflusses & 
Rekonstruktion des 
Ursprungsgefäßes 
Methode: basierend auf 
EuNetHTA Core Model; 
systematische 
Literatursuche in  
4 Datenbanken; GRADE 
Einschlusskriterien  
für Wirksamkeit 
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Gesamtmortalität, Behinderung/Abhängigkeit, gesundheitsbezogene Lebens-
qualität, Wiederbehandlungsrate und angiographische Surrogatparameter 
(Aneurysmaverschluss und Stammgefäßverengung). 
Sicherheit 
Für die Analyse der Sicherheit der Behandlung mit Flow Divertern wurden 
prospektive, kontrollierte und unkontrollierte Studien mit Follow-up ≥6 Mo-
naten eingeschlossen. Unkontrollierte Studien wurden nur eingeschlossen, 
wenn sie entweder ≥200 Teilnehmer hatten, oder ≥50 Teilnehmer und au-
ßer der Mortalität weitere Nebenwirkungen berichteten. Die entscheidenden 
Endpunkte, anhand derer eine Empfehlung abgeleitet wurde, sind: neurolo-
gischer Tod, Hämorrhagie (gesamt und früh), ischämischer Schlaganfall (ge-
samt und früh), neue oder verschlechterte Behinderung/Abhängigkeit. 
 
Ergebnisse 
Verfügbare Evidenz 
Fünf prospektive, multizentrische, unkontrolliert Studien wurden identifi-
ziert, die die Wirksamkeit und Sicherheit der Behandlung mit Flow Diver-
tern in rupturierten intrakraniellen Aneurysmen untersuchten, wobei unter-
schiedliche Einschlusskriterien für „schwer zu behandelnde“ Aneurysmen 
herangezogen wurden (große, breithalsige, fusiforme IA, etc.). Insgesamt wur-
den Ergebnisse von 494 Patienten, die mit Flow Divertern behandelt wur-
den, berichtet. 
Klinische Wirksamkeit 
Die Gesamtmortalität lag in den fünf Studien bei 0 bis 8 %. Eine erneute 
Behandlung der Aneurysmen war laut zwei Studien in 0 bis 4,5 % erforder-
lich. Angiographische Wirksamkeit lag bei 49 bis 85,7 % nach sechs Mona-
ten und 81 bis 86,6 % nach einem Jahr; gleichzeitig kam es zu Stammgefäß-
verengungen ≥50 % in 0 bis 16,3 %. Eine verbesserte Funktion wurde in 
zwei Studien in 8,4 % and 19,6 % der TeilnehmerInnen berichtet. Direkte 
Evidenz zur Überlegenheit der Flow Diverter im Vergleich zu alternativen 
Behandlungsmöglichkeiten hinsichtlich der Wirksamkeitsendpunkte steht 
nicht zur Verfügung. 
Sicherheit 
Nach 6 Monaten berichteten die 5 Studien das Auftreten neurologischen To-
des in 0 bis 2,8 %. Hämorrhagien traten bei 0–6,2 % der TeilnehmerInnen auf, 
wobei späte Blutung (≥30 Tage) 0 bis 2 % betrafen. Ischämischer Schlagan-
fall trat in 0 bis 3,7 % auf. Eine verschlechterte Funktion wurde für 2,7 bis 
14 % der Teilnehmer berichtet. Direkte Evidenz zur Überlegenheit der Flow 
Diverter im Vergleich zu alternativen Behandlungsmöglichkeiten hinsicht-
lich der Sicherheitsendpunkte steht nicht zur Verfügung. 
Laufende Studien 
Fünf RCTs mit Flow Divertern als Intervention sind derzeit registriert: vier 
davon zielen auf die Behandlung „schwer zu behandelnder“ Aneurysmen mit 
unterschiedlichen Einschlusskriterien (z. B. breithalsig, groß). Die frühesten 
Ergebnisse zur Wirksamkeit und Sicherheit der Flow Diverter im Vergleich 
zur Standardbehandlung werden nach dem Abschluss der FIAT Studie im 
April 2016 erwartet. 
Einschlusskriterien  
für Sicherheit 
5 prospektive, 
multizentrische, 
unkontrollierte Studien 
Mortalität 0 bis 8 %; 
Aneurysmaverschluss 
49-85,7 % (6 mo) 
Nebenwirkungen:  
Tod, Hämorrhagie, 
Schlaganfall 
5 laufende RCTs 
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Diskussion 
Flow Diverter werden als Behandlungsoption für ansonsten unheilbare An-
eurysmen angepriesen. In der Praxis jedoch gibt es keine einheitliche Defi-
nition „unheilbarer“ Aneurysmen, wie die heterogenen Einschlusskriterien 
der Studien unterstreichen. Bei den meisten Patienten ist eine alternative 
Standardbehandlung tatsächlich möglich und der Trade-off der Verfahrens-
risiken gegenüber der langfristigen klinischen Ergebnisse muss anhand von 
RCTs ermittelt werden. 
 
Empfehlung 
Es gibt moderate Evidenz für die Wirksamkeit basierend auf dem angiogra-
phischen Surrogatparameter Aneurysmaverschluss in einem großen Prozent-
satz der behandelten Aneurysmen. 
Die aktuellen Erkenntnisse sind jedoch nicht ausreichend, um zu zeigen, 
dass die endovaskuläre Embolisation mit Flow Divertern in Bezug auf die 
klinischen Ergebnisse wirksamer und sicher ist als gar keine Behandlung, 
endovaskuläres Coiling oder operatives Clipping. 
Die Neubewertung wird im Jahr 2017 empfohlen, vorausgesetzt, dass die Da-
ten aus randomisiert kontrollierten Studien zu diesem Zeitpunkt zur Verfü-
gung stehen. 
 
keine klare Definition 
von „unbehandelbaren“ 
Aneurysmen  
Surrogatparameter 
Aneurysmaverschluss: 
moderate Evidenz 
ungenügende Evidenz 
hinsichtlich klinischer 
Endpunkte im Vergleich 
zu Behandlungs-
alternativen 
 
Re-evaluierung 2017  
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1 Scope 
1.1 Research questions 
Is the endovascular embolization with flow diverters in comparison to endo-
vascular coiling, microsurgical clipping or no treatment in adult patients with 
a) unruptured intracranial aneurysms (IA) and b) unruptured large/giant, 
fusiform or wide-necked IA more effective and safe concerning overall mor-
tality, disability-free survival and treatment-associated morbidity?  
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1.2-1. 
Table 1.2-1: Inclusion criteria 
Population A) First-line treatment in adult patients with unruptured intracranial aneurysms. 
International classification of diseases (ICD)-10-CM code: I67.1 Cerebral aneurysm, unruptured 
MeSH terms: Intracranial aneurysm  
B) First- or second-line treatment in adult patients with unruptured large/giant, wide-necked 
and fusiform intracranial aneurysms, for whom stent-assisted coil embolization and/or 
neurosurgical techniques are not considered feasible (de novo or repeat treatment).  
ICD-10-CM code: I67.1 Cerebral aneurysm, unruptured 
MeSH terms: giant intracranial aneurysm, intracranial aneurysm  
Patients with ruptured aneurysms and paediatric patients are excluded from the scope.  
Intervention Therapeutic embolization of the aneurysm by endovascular (catheter-based) implantation of a 
flow diverter/flow modulating device across the neck of the aneurysm alone or in association 
with embolization coils. 
MeSH terms: E02.520.360 or E02.926.500 
Comparators1 Observation (natural course of the disease) 
Endovascular coiling 
Neurosurgical clipping 
Outcomes  
Efficacy Overall mortality  
Disability/Dependency 
Health-related quality of life (HRQoL) 
Primary surrogate parameter: 
Aneurysm occlusion  
Parent artery stenosis 
Aneurysm recurrence/retreatment rate 
Safety Peri-operative and post-operative therapy-associated mortality  
Peri-operative and post-operative therapy-associated morbidity  
Disability/Dependency  
 
                                                             
1 Comparators were selected based on recommended treatment options included in 
Austrian/German guidelines for unruptured intracranial aneurysms. 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Study design  
Efficacy  RCTs with follow-up ≥6 months 
(Only for Population B: prospective non-randomised controlled trials and prospective  
single-group studies with follow-up ≥6 months if ≥50 patients 
Safety RCTs with follow-up ≥6 months  
Prospective non-randomised controlled studies ≥6 months 
Prospective single-group studies with follow-up ≥6 months if a) ≥200 patients or  
b) ≥50 patients and reporting of mortality AND further adverse events 
 
 
1.3 Literature search 
The systematic literature search was conducted on the 12th of December 2014 
in the following databases:  
 Medline via Ovid 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
and complemented with a Scopus Search in the references of key articles. 
Search filters were applied (in MEDLINE and Embase) to limit the results to 
Clinical Trials and Systematic Reviews/Meta-Analyses. After deduplication, 
389 citations were included for abstract screening. The specific search strat-
egies employed can be found in the Appendix.  
The manufacturers of all marketed products were asked to submit further 
publications. One (Covidien, Pipeline Embolization Device) submitted 88 
publications of which one new relevant citation was identified, resulting in 
390 hits overall. 
 
  
systematische 
Literatursuche in  
vier Datenbanken  
insgesamt 390 
Referenzen identifiziert 
Scope 
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1.4 Flow chart of study selection 
Overall, 390 hits were identified. The references were screened by two inde-
pendent researchers and in case of disagreement a third researcher was in-
volved to solve the differences. The selection process is displayed in Figure 
1.4-1. 
 
Figure 1.4-1: Flow chart of study selection (PRISMA Flow Diagram) 
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2 Description and technical 
characteristics of technology 
2.1 Methods 
Research questions 
Element ID Research question 
Importance 
2 = critical 
1 = optional 
B0001 What are flow diverters and what are the alternative standard 
treatment options? 
2 
A0020 For which indications have flow diverters received marketing 
authorisation or CE marking? 
2 
B0002 What is the approved indication and claimed benefit of flow diverters 
in relation to the comparators? 
2 
B0003 What is the phase of development and implementation of flow 
diverters and the comparator(s)? 
2 
B0004  Who performs or administers flow diverters and the comparators and 
in what context and level of care are they provided? 
2 
B0008 What kind of special premises are needed to use flow diverters and the 
comparator(s)? 
2 
B0009 What supplies are needed to use flow diverters and the comparator(s)? 2 
 
Sources 
 Handsearch in the POP, AdHopHTA and CRD databases for Health 
Technology Assessments 
 Background publications identified in database search: see Section 1.3 
 Documentation provided by the manufacturers 
 Questionnaire completed by the submitting hospitals  
 
 
2.2 Results 
Features of the technology and comparators 
B0001 – What are flow diverters and what are the alternative standard 
treatment options? 
Flow diverters are tubular, braided metallic stents that are deployed endo-
vascularly to treat aneurysms [1, 2] through two mechanisms:  
1. Flow diverters are placed in the parent artery across the aneurysm neck 
rather than in the aneurysm sac. There, through their dense mesh 
structure, they re-direct the blood flow at the aneurysm/parent vessel 
interface to induce thrombosis and occlusion within the aneurysm sac.  
2. The stent is subsequently overgrown, leading to endoluminal recon-
struction of the parent artery.  
Quellen 
FD: schlauchförmige 
Stents aus einem 
Metallgeflecht. 
Wirkungsmechanismus: 
1) Ableitung des 
Blutflusses aus 
Aneurysma  
2) Rekonstruktion des 
Ursprungsgefäßes 
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Flow diverter techniques thereby lead to aneurysm occlusion over time rather 
than immediately after the intervention. 
Important metrics for flow diversion efficacy are the porosity/metal coverage 
(proportion of open metal-free and closed metal-covered area across the an-
eurysm neck, respectively) and pore density (number of pores per area), with 
lower porosity and higher pore density being optimal conditions for aneurysm 
occlusion [2].  
Another class of flow diverters (e.g., Woven EndoBridge, WEB, LUNA AES) 
are placed intrasaccularly (within the aneurysm sac) rather than intravascu-
larly (in the parent vessel) and are not within the scope of this review. 
Marketed products 
Several endovascular flow diverters have received marketing authorisation in 
Europe and/or in the USA (Table 2.2-1): 
The PipelineTM Embolization device (PED) consists of a braided, multi-alloy, 
mesh cylinder implant woven from cobalt/chromium/molybdenum/nickel and 
platinum/tungsten alloy wires. It has a porosity of 65-70% [1]. A delivery sys-
tem is provided with the implant mounted on a micro-guidewire and com-
pressed inside an introducer sheath. The PipelineTM Flex Embolization de-
vice (PFED) is an iteration of the PED with a modified delivery system al-
lowing repositioning of the device (information from the manufacturer). 
The SILK device is a self-expanding flow diverter composed of a braided mesh 
cylinder with flared ends, made of 48 braided nickel-titanium (nitinol) alloy 
and platinum microfilament strands [2]. It has a porosity of 45–60% [1]. It is 
provided with a delivery system. The SILK+ is an iteration of the SILK de-
vice with higher radio-opacity and the possibility for repositioning (informa-
tion from the manufacturer). 
The Surpass device is a self-expanding flow diverter constructed of cobalt 
chromium braids with 12 platinum-tungsten wires, shaped in a tubular, low 
porosity mesh. It is provided with a delivery system composed of a delivery 
catheter and a pusher [2]. It has a porosity of 70% [1]. 
The FREDTM device has a self-expandable stent-within-a-stent design. The 
device consists of a paired, dual-layer design with an outer high-porosity stent 
and a narrower inner flow-diverter mesh composed of 48 braided nitinol 
strands. It can be partially deployed, retrieved and repositioned (information 
from the manufacturer). 
The p64 flow modulation device is composed of a 64 nitinol wire braid. It al-
lows repositioning even after full deployment and is provided with a delivery 
system (information from the manufacturer).  
The Derivo® embolization device is a nitinol wire braid equipped with a ni-
tinol transport wire and can be recaptured and repositioned. It is provided 
with a delivery system (information from the manufacturer). 
Microsurgical clipping 
Surgical clipping involves placing a small metal clip across the aneurysm’s 
neck with preservation of the parent vessel and arterial branches. It requires 
craniotomy and brain retraction. This has been the historical definitive stand-
ard for the treatment of IA [3].  
Verschluss erst nach 
einiger Zeit 
Stärke der 
Blutflussableitung 
abhängig von Porosität 
und Porendichte des FD 
mehrere Produkte mit 
Marktzulassung 
PipelineTM Embolization 
device 
SILK 
Surpass 
FREDTM 
p64 modulation device 
Derivo® embolization 
device 
operatives Clipping: 
Setzen einer 
Metallklammer um  
den Hals des IA 
Description and technical characteristics of technology 
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Endovascular coiling 
A variety of endovascular treatments have been developed in the past years. 
They are all based on the use of a percutaneous catheter system to repair the 
aneurysm from within the vessel, sparing the need for a craniotomy. A micro-
catheter is introduced in the intracranial circulation, usually from a femoral 
artery approach, and positioned within the aneurysm. Through the micro-
catheter a first coil is introduced in the aneurysm sac, forming a basket ap-
posed to the aneurysm wall. Additional coils are introduced until the sac is 
densely packed and the micro-catheter can be removed [4]. 
 
A0020 – For which indications have flow diverters received marketing 
authorisation or CE marking? 
Table 2.2-1: Regulatory history of flow diverter products 
Product name Manufacturer Date Indication for use Date Indication for use 
PipelineTM 
Embolization 
Device 
(ev3/Covidien) 
Medtronic, 
Dublin, IE 
Jun 2008: 
489211A 
The PED is intended for 
endovascular embolization 
of cerebral aneurysms. 
Apr 2011: 
P100018 
Endovascular treatment of 
adults (age 22 and above) 
with large or giant wide-
necked IAs in the internal 
carotid artery from the 
petrous to the superior 
hypophyseal segments. 
Pipeline Flex 
Embolization 
Device 
(ev3/Covidien) 
Medtronic, 
Dublin, IE 
Mar 2014: 
489211A 
The PFED is intended for 
endovascular embolization 
of cerebral aneurysms. 
Feb 2015 Endovascular treatment of 
complex intracranial 
aneurysms that are not 
amenable to treatment 
with surgical clipping and 
are attached to parent 
vessels measuring 2.5 to  
5.0 mm in diameter 
Silk flow 
diverter 
Balt Extrusion, 
Montmorency, 
FR 
Jan 2008 The treatment of 
intracranial aneurysms  
in association with 
embolization coils 
Not approved 
Surpass flow 
diverter 
Stryker 
Neurovascular, 
Fremont, Cal, 
US 
Aug 2011 Saccular or fusiform 
intracranial aneurysms 
arising from a parent 
vessel with a diameter of 
≥2 mm and ≤5.3 mm 
Not approved 
FredTM (Flow 
redirection 
endoluminal 
device) 
MicroVention, 
Tustin, Cal, US  
Dec 2013 Information not available Not approved 
P64 Flow 
Modulation 
Device 
Phenox, 
Bochum, DE 
Oct 2012 Information not available Not approved 
Derivo® 
Embolization 
Device 
Acandis, 
Pforzheim, DE 
Oct 2012 The DERIVO® Embolization 
Device is intended for the 
treatment of intracranial 
aneurysms. It is suitable 
for vessel diameters from  
3 to 6 mm  
Not approved 
 
endovaskuläres Coiling: 
Zugang über 
Mikrokatheter und 
Auffüllung des 
Aneurysmasacks mit 
Platinumspiralen 
Zulassungshistorie  
der FD Produkte 
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B0002 – What is the claimed benefit of flow diverters in  
relation to the comparators? 
The treatment of IA with flow diverters responds to an unmet need in clini-
cal situations not amenable to existing treatments (surgical clipping or endo-
vascular coiling) or associated with a major risk of morbidity and mortality. 
In these situations, the claimed benefit consists in the stable occlusion of the 
aneurysm and, thereby, the decreased risk of rupture and prevention of func-
tional impairment or death following subarachnoid haemorrhage (SAH) as 
compared to the untreated aneurysm.  
In comparison to surgical clipping, the claimed benefits of the treatment with 
flow diverters are comparable occlusion and recurrence rates and fewer pro-
cedural risks.  
For IA that can be treated by endovascular coiling, treatment of IA with flow 
diverters responds to a medical need that is already met.  
 
B0003 – What is the phase of development and implementation  
of flow diverters and the comparator(s)? 
The first flow diverters received a CE mark in 2008, and FDA pre-market 
approval in 2011 (Table 2.2-1). It is a novel technology that has not previous-
ly been used for other purposes and is not yet established in use. Iterations 
of the products are currently emerging, allowing, for example, the reposition-
ing or retraction of the device. No RCT has so far been completed and pub-
lished on flow diverters; five RCT are currently registered (Table A3-1). 
Surgical clipping: The first aneurysm ever treated by surgical clipping was 
performed in 1937. Microsurgical clipping is now a well-established stand-
ard technique.  
Endovascular coiling: Endovascular treatment of IA has evolved over the past 
30 years. Initially, detachable balloons were used, but they were replaced by 
fibre coils, allowing a better adaptation to the aneurysm shape. The endovas-
cular treatment of IA with detachable flexible platinum coils is now a well-
established standard technique. 
 
Administration, investments, personnel and tools required  
to use the technology and the comparator(s) 
B0004 – Who administers flow diverters and the comparators and  
in what context and level of care are they provided? 
B0008 – What kind of special premises are needed to use flow diverters 
and the comparator(s)? 
B0009 – What supplies are needed to use flow diverters and  
the comparator(s)? 
The treatment of IA is performed in university hospitals and specialised cen-
tres with expertise in both interventional neuroradiology and neurosurgery. 
To ensure the selection of the most appropriate treatment approach, patients 
should be evaluated by an interdisciplinary team including both a neurosur-
geon and an endovascular specialist. 
nicht durch Clipping oder 
Coiling behandelbare IA: 
ungedeckter Bedarf. 
Nutzen liegt in 
Prävention der Ruptur 
bei nur durch  
operative Verfahren 
behandelbaren IA: 
Nutzen durch geringere 
prozedurale Risiken 
FD: erste  
CE-Zertifizierung 2008, 
vorläufige FDA 
Zulassung 2011 
operatives Clipping: 
etablierte 
Standardmethode 
endovaskuläres Coiling: 
etablierte 
Standardmethode 
IA Behandlung in 
Zentren mit Expertise in 
Neuroradiologie und 
Neurochirurgie 
Description and technical characteristics of technology 
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The endovascular embolization (either with coils or with flow diverters) is per-
formed under general anaesthesia by using biplane angiography units and a 
transfemoral artery approach. Frequently the flow diverters are used in ad-
dition to endovascular coiling. Similar to conventional stenting, patients re-
ceive dual antiplatelet therapy (aspirin and clopidogrel) to prevent stent 
thrombosis prior to the procedure and for at least six months after the pro-
cedure [5]. 
 
endovaskuläre 
Behandlung benötigt 
Zweiebenen-
Angiographie-Einheiten 
 
begleitend: Therapie  
mit Thrombozyten-
aggregationshemmern 
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3 Health problem and current use 
3.1 Methods 
Research questions  
Element ID Research question 
Importance 
2 = critical 
1 = optional 
A0001 For which health conditions, and for what purposes are flow diverters 
indicated? 
2 
A0002 What indications of flow diverters are in the scope of this assessment? 2 
A0003 What are the known risk factors for the development and rupture of 
intracranial aneurysms? 
2 
A0004 What is the natural course of intracranial aneurysms? 2 
A0005 What is the burden of disease for patients with unruptured intracranial 
aneurysms? 
2 
A0006 What is the burden of intracranial aneurysms for society? 2 
A0024 How are intracranial aneurysms currently diagnosed according to 
published guidelines and in practice? 
2 
A0025 How are intracranial aneurysms currently managed according to 
published guidelines and in practice? 
2 
A0007 What is the target population in this assessment? 2 
A0023 How many people belong to the target population? 2 
A0011 What is the expected annual utilisation of flow diverters? 2 
 
Sources 
 Hand search in the POP, AdHopHTA and CRD databases for Health 
Technology Assessments 
 Background literature identified during systematic literature search: 
see Section 1.3 
 Hand search for clinical guidelines on the websites of the Austrian 
Society of Neurology (www.oegn.at) and the German Society of 
Neurology (www.dgn.at), on BMJ Best practice [6] and UptoDate® 
(http://www.uptodate.com). 
 Questionnaire completed by the submitting hospitals  
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3.2 Results 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
are flow diverters indicated?  
A0002 – What indications of flow diverters are in the scope of this 
assessment?  
In Europe, flow diverters have a broad indication for the endovascular emboli-
zation of any IA (without anatomic limitation). Ruptured aneurysms would 
probably not be amenable to the treatment with flow diverters because dual 
platelet therapy (aspirin and clopidogrel) would be needed with the therapy 
and the use of anticoagulation medications is relatively contraindicated in 
cases of ruptured aneurysm. In the scope of this assessment, therefore, only 
unruptured IA in adults are included.  
 
A0004 – What is the natural course of intracranial aneurysms?  
IA (also termed cerebral aneurysms or brain aneurysms) are localised abnor-
mal dilations of the wall of arteries that supply blood to the brain which 
usually develop from a weakness in the blood vessel wall. They are classified 
according to morphology, size and location [6, 7]:  
Morphology 
Saccular (also: berry) aneurysms are IA with a rounded outpouching attached 
by a neck or stem to the brain artery. They usually arise from arterial bifur-
cation points. 
Fusiform (also: atherosclerotic) aneurysms form as tunica media damage leads 
to arterial stretching and elongation. 
Dissecting IA arise from arterial dissections where an intramural hematoma 
extends into the subadventitial plane, forming a sac-like outpouching. They 
may arise spontaneously, but more commonly they are induced by a trauma 
or an underlying vasopathy. 
Size 
Aneurysms with a diameter ≥25mm are classified as giant aneurysms. They 
are thought to represent about 5–8% of all saccular IA.  
In contrast to giant aneurysms, there are no standardised cut-offs for small 
and large aneurysms (sometimes classifications include a “medium” catego-
ry.). Classification as ‘small’ aneurysms may include aneurysms with maxi-
mum diameters of 7mm up to 12mm; classification as ‘large’ aneurysms may 
include aneurysms with minimum diameters of 10mm up to 20mm (but be-
low 25mm). The majority of IA (>90%) are <10mm [8, 9]. 
Location 
The majority of IA (>85%) develop in the anterior part of the Circle of Willis 
and involve the internal carotid arteries and their major branches [9].  
IA located in the basilar artery bifurcation and the remaining posterior cir-
culation arteries are less common and more difficult to treat due to their 
limited accessibility. 
Europa:  
indiziert für 
endovaskuläre 
Embolisation aller IA 
 
rupturierte IA 
ausgeschlossen 
IA: lokalisierte 
Aussackungen der 
Blutgefäße 
sakkulär 
fusiform 
Aortendissektion 
Diameter ≥ 25 mm: 
Riesenaneurysma 
Diameter ≥ ca. 10 mm: 
großes Aneurysma 
>85 % der IA:  
vordere Zirkulation 
IA der hinteren 
Zirkulation schwerer 
zugänglich 
Health problem and current use 
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Small, unruptured IA are usually asymptomatic. In larger IA, symptoms may 
be caused by the compression of adjacent structures, e.g. the oculomotor nerve.  
The mortality and morbidity of an unruptured IA depends mainly on its risk 
of rupture, resulting in SAH as the major rupture manifestation or parenchy-
mal haemorrhage. In a major study with >4,000 patients (International Study 
of Unruptured Intracranial Aneurysms, ISUIA) the risk of rupture was esti-
mated to be 1.2% per year [10], but it increases in relation to aneurysm size 
and location and whether or not the patient has already had a SAH from an-
other aneurysm (Table 3.2-1).  
Table 3.2-1: Five-year cumulative rupture rates for patients with untreated IA 
Size Cavernous carotid artery (%) Anterior circulation (%) Posterior circulation (%) 
<7mm and previous SAH 0 1.5 3.4 
<7mm no previous SAH 0 0 2.5 
7–12mm 0 2.6 14.5 
13–24mm 3.0 14.5 18.4 
>24mm 6.4 40 50 
Source: [10] SAH = Subarachnoid Haemorrhage 
 
SAH is bleeding into the fluid-filled spaces surrounding the brain. 32–67% of 
SAH result in death with more than 20% long-term dependency in survivors 
[7]. The Hunt and Hess classification is used to grade the clinical status of a 
patient with SAH (Table 3.2-2).  
Table 3.2-2: Hunt and Hess classification of the clinical status of patients with SAH 
Grade Clinical condition at presentation 
0 Unruptured aneurysm 
1 Asymptomatic or minimal headache, slight nuchal rigidity 
2 Moderately severe or severe headache, nuchal rigidity, no neurological deficit other than cranial 
nerve palsy 
3 Drowsiness, confusion, or mild focal deficit 
4 Stupor, moderate to severe hemiparesis, possible early decerebrate rigidity and vegetative disturbances 
5 Deep coma, decerebrate rigidity, moribund appearance 
Source: [11] SAH = Subarachnoid Haemorrhage 
 
A0003 – What are the known risk factors for the development and 
rupture of intracranial aneurysms? 
Known risk factors for the development of an IA are a family history of an-
eurysm, certain inherited disorders (e.g. autosomal dominant polycystic kid-
ney disease), atherosclerosis, age greater than 50 years, female gender, current 
cigarette smoking and use of cocaine [8, 9]. 
In addition to larger size, location in the posterior circulation and the IA be-
ing symptomatic, age of the patients >60 years, female gender, hypertension, 
certain behavioural aspects (smoking and drinking habits) are risk factors for 
rupture. Finnish or Japanese populations also have a higher risk of rupture 
[12-14]. 
 
IA üblicherweise 
asymptomatisch 
Mortalität und 
Morbidität aufgrund  
des Rupturrisikos: 
subarachnoidale 
Blutung (SAH) 
SAH:  
hohes Risiko für Tod 
oder Pflegebedürftigkeit 
Risikofaktoren  
für Entstehung 
Risikofaktoren  
für Ruptur 
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Effects of the disease or health condition  
on the individual and society 
A0005 – What is the burden of disease for patients with unruptured 
intracranial aneurysms?  
Most unruptured IA are asymptomatic and the risk of rupture is low. Many 
unruptured IA are detected incidentally by brain imaging obtained for anoth-
er condition. No major impact on QOL, anxiety, and depression was found 
associated with being aware of having an untreated, unruptured IA [15, 16]; 
however a minor impact is possible.  
Some unruptured IA can become symptomatic [17]. Symptoms include head-
ache (which may be severe and comparable to the headache of SAH), visual 
acuity loss, cranial neuropathies (particularly third nerve palsy), pyramidal 
tract dysfunction, and facial pain; these are explained with the mass effect of 
the aneurysm (i.e. the compression of adjacent structures and nerves). Ische-
mia can occur as a result of emboli originating from within an aneurysm. 10-
15% of IA are symptomatic [10, 18]. 
A variety of functional assessment scales are used to measure the degree of 
disability or dependence in the daily activities of people who have suffered a 
stroke or other causes of neurological disabilities [11]. The most widely used 
clinical outcome measure is the modified Rankin Scale (mRS) (Table 3.2-3). 
Table 3.2-3: Modified Rankin Scale (mRS) 
Score Description 
0 No symptoms. 
1 No significant disability. Able to carry out all usual activities, despite some symptoms. 
2 Slight disability. Able to look after own affairs without assistance, but unable to carry out all 
previous activities. 
3 Moderate disability. Requires some help, but able to walk unassisted. 
4 Moderately severe disability. Unable to attend to own bodily needs without assistance, and 
unable to walk unassisted. 
5 Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 
6 Dead. 
 
A0006 – What is the burden of intracranial aneurysms for society? 
The overall prevalence of IA for adults without specific risk factors is approx-
imately 3% [9]. Most IA are small, asymptomatic and have a low risk of rupture. 
 
Current clinical management of the disease or health condition 
A0024 – How are intracranial aneurysms currently diagnosed according 
to published guidelines and in practice? 
Most cerebral aneurysms go unnoticed until they rupture or are detected by 
brain imaging that may have been obtained for another condition. Unrup-
tured IA may be differentiated as: 
 incidental aneurysms: true incidental finding without SAH or other 
symptoms 
 symptomatic aneurysms (e.g., compression of oculomotor nerve) 
 additional aneurysms (found in patients following rupture of another 
aneurysm) 
Mehrheit der IA 
asymptomatisch, 
geringes Rupturrisiko 
10–15 % der IA 
verursachen Symptome 
durch Gehirnnerven-
kompression 
modifizierte Rankin 
Skala: Ausmaß der 
neurologischen 
Beeinträchtigung 
Prävalenz der IA:  
ca. 3 % 
unrupturierte IA:  
häufig Zufallsbefunde 
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The accepted reference standard method for the identification of intracrani-
al aneurysms is intra-arterial digital subtraction angiography [19]. 
Both magnetic resonance angiography (MRA) and the computed tomography 
angiography (CTA) using contrast dyes have an overall accuracy of ~90% for 
aneurysms >4-6mm diameter [19]. Smaller aneurysms are less reliably de-
tected. Use of multi-detector CTA or MRA at 3.0 Tesla may improve sensi-
tivity for smaller aneurysms. In the absence of SAH, findings of aneurysms 
<7mm have a higher likelihood of being false positives and require confir-
mation [19]. 
 
A0025 – How are intracranial aneurysms currently managed  
according to published guidelines and in practice? 
Unruptured IA are treated electively, with the three major treatment options 
being observation, surgical clipping and endovascular coiling [20]. The risks 
of each treatment option need to be weighed against the natural history risks. 
These vary depending on factors specific both to patients (age, co-morbidities, 
etc.) and to the aneurysm (size, location, morphology, previous rupture).  
Observation 
The indication for treatment of very small, unruptured IA is controversial, 
as the risk of SAH is small [21]. The risk of perforation during endovascular 
treatment is higher in very small IA (<3mm). Therefore, these IA are some-
times managed conservatively through periodic fluoroscopic and angiograph-
ic surveillance, together with treatment for risk factors such as hypertension 
or smoking. 
Age is a crucial element in deciding whether to treat an unruptured aneurysm 
[10]. While age has relatively little effect on the natural course of unrup-
tured aneurysms, morbidity and mortality are increased with open surgery in 
patients ≥50 years and with endovascular procedures in patients ≥70 years. 
In contrast, young (<50 years) patients should be considered for treatment 
due to the higher life-time risk of rupture [22].  
Surgical clipping 
A systematic review and meta-analysis of 60 observational studies with 9,845 
patients and 10,845 aneurysms found that the overall mortality associated 
with surgical clipping of unruptured aneurysms was 1.7 percent and unfa-
vourable outcomes occurred in 6.7 percent of the patients [23]. Risk factors 
for poor safety outcomes include advanced age, larger aneurysm size, and lo-
cation in the posterior circulation; the association with these risk factors is 
more consistently observed in surgically rather than endovascularly treated 
patients [10, 24]. 
Surgical treatment of IA in the posterior circulation is particularly challeng-
ing due to the proximity of the brain stem and cranial nerves [7].  
Endovascular treatment 
The main endovascular technology used to treat IA is embolization with de-
tachable flexible platinum coils.  
In the ISUIA dataset, rates of poor neurologic outcome at one year were 12.6 
percent and 9.8 percent for those treated surgically and endovascularly re-
spectively [10]. A meta-analysis of the literature from 2003 to 2011 on the 
Referenzstandard: 
intraarterielle digitale 
Subtraktions-
angiographie 
 
Diagnose auch mittels 
MRA oder CTA 
Behandlungsoptionen: 
Beobachtung, 
operatives Clipping oder 
endovaskuläres Coiling 
Beobachtung: bei IA mit 
niedrigem Rupturrisiko, 
höherem Alter der 
PatientInnen 
operatives Clipping: 
steigendes Risiko für 
ungünstigen Ausgang 
bei zunehmendem Alter 
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Behandlung 
möglicherweise 
komplikationsärmer  
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treatment-related risks of endovascular treatment for unruptured, saccular 
IA, found a procedure-related unfavourable outcome, including mortality, in 
4.7% (99% CI, 3.8% to 5.7%) of the patients and a mortality rate of 1.8% 
(fixed-effect weighted average: 99% CI, 1.4% to 2.4%) [25]. However, in the 
absence of randomisation, differences in mortality and morbidity between 
endovascular treatment and surgical clipping are likely to be distorted by se-
lection bias, as patients with more difficult aneurysms may preferentially be 
referred to surgery. 
Wide-necked aneurysms are traditionally treated with surgical clipping, as 
standard coiling could result in coil herniation and parent artery occlusion 
[7]. Giant aneurysms or fusiform aneurysms may neither be treated by sim-
ple coiling approaches nor by surgical clipping, due to the neck morphology 
of these aneurysms [7]. Therefore, the remaining – surgical – approaches are 
parent vessel occlusion with or without bypass. 
 
Target population 
A0007 – What is the target population in this assessment?  
A0023 – How many people belong to the target population?  
In Europe, flow diverters have received CE marking for the treatment of in-
tracranial aneurysms without further specification.  
Thus, we chose all adult persons with unruptured intracranial aneurysms as 
our primary target population. Referring to an estimated prevalence of 3% 
[9], this would correspond to roughly 200,000 affected adult persons in Aus-
tria. It must not be forgotten in this context that a large proportion of these 
aneurysms would be subclinical and likely undiagnosed. 
In the USA and Canada, flow diverters have received more restrictive mar-
keting authorisations, limiting their use to “endovascular treatment of adults 
with large or giant wide-necked IAs in the internal carotid artery from the 
petrous to the superior hypophyseal segments” (Pipeline Embolization De-
vice) and “endovascular treatment of complex intracranial aneurysms that 
are not amenable to treatment with surgical clipping” (Pipeline Flex Embo-
lization Device), consistent with the respectively claimed benefit. We there-
fore defined a second target population restricted to adult patients with un-
ruptured large/giant, wide-necked saccular or fusiform intracranial aneu-
rysms, for whom stent-assisted coil embolization and/or neurosurgical tech-
niques are not considered feasible (de novo or repeat treatment). The per-
centage of aneurysms ≥10mm is estimated to be 7% [9], reducing their pre-
valence to roughly 1 in 500 subjects. 
 
A0011 – What is the expected annual utilisation of flow diverters? 
In 2013, 10 treatments with flow diverters were recorded. The expected annual 
utilisation in Austria is estimated to be 40 treatments (estimates provided by 
the submitting hospital). 
 
Coiling nicht möglich  
für breithalsige IA, 
Riesenaneurysmen  
primäre Zielpopulation: 
Erwachsene mit 
unrupturierten IA 
sekundäre 
Zielpopulation: 
Erwachsene mit 
unrupturierten IA, 
Einschränkung auf 
große, breitbasige, 
fusiforme IA oder 
Riesen-IA 
ca. 40 Behandlungen 
jährlich erwartet  
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4 Clinical effectiveness 
4.1 Methods 
Research questions 
Element ID Research question 
Importance 
2 = critical 
1 = optional 
D0001 What is the expected beneficial effect of flow diverters on mortality? 2 
D0002 What is the expected beneficial effect of flow diverters on  
disease-specific mortality? 
2 
D0003 What is the effect of flow diverters on the mortality due to causes other 
than the target disease? 
1 
D0005 How do flow diverters affect symptoms and findings (severity, 
frequency) of intracranial aneurysms? 
2 
D0006 How do flow diverters affect progression (or recurrence) of intracranial 
aneurysms? 
2 
D0011 What is the effect of flow diverters on patients’ body functions? 2 
D0016 How does the use of flow diverters affect activities of daily living? 2 
D0012 What is the effect of flow diverters on generic health-related quality of life? 2 
D0013 What is the effect of flow diverters on disease-specific quality of life? 2 
D0017 Was the use of flow diverters worthwhile? 1 
 
Flow diverters are used for the preventive treatment of unruptured IA; hence, 
long-term outcomes are required to assess the reduced risk of rupture and 
associated reduction in mortality and morbidity. 
Endpoints for assessing clinical effectiveness were derived from the three 
main categories of endpoints “mortality”, “morbidity” and “quality of life” 
that have been defined in the EUnetHTA guideline on clinical endpoints [Eu-
ropean Network for Health Technology Assessment (EUnetHTA) 2013a]. 
The following crucial outcomes were used as evidence to derive a  
recommendation: 
 Overall mortality (1 year/5 years)  
 Disability/Dependency (1 year/5 years) 
 Health related quality of life (HRQoL) 
 Primary surrogate parameters: 
 Complete aneurysm occlusion (1 year/5 years) 
 Parent artery stenosis (1 year/5 year) 
 Aneurysm recurrence/retreatment rate (1 year/5 years) 
The most commonly used tool to evaluate the clinical outcomes of IA inter-
ventions is the modified Rankin Scale (mRS, Table 3.2-3), which measures 
the presence of symptoms, the degree of a patient’s functional disability, neu-
rological disability or death with acceptable inter-rater variability [26]. 
FD für 
Präventivbehandlung: 
langfristige Endpunkte 
notwendig 
entscheidende 
Endpunkte: 
- Mortalität 
- Pflegebedürftigkeit 
- Lebensqualität 
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Angiographic endpoints (aneurysm occlusion and parent artery stenosis) were 
considered, but in the knowledge that they are surrogate endpoints and the 
relation to the final therapeutic objective (prevention of rupture) cannot be 
directly extrapolated. Apart from that, relevant inter-observer variability might 
be an issue [27]. Angiographic aneurysm occlusion is measured by digital sub-
traction angiography (DSA) as the gold standard (alternatively by MRA or 
CTA) and classified according to the Raymond or Montreal scale in the clas-
ses “complete”, “residual neck” or “residual aneurysm” [28]. Parent artery 
stenosis is measured by the method of Samuels [29]. 
Angiographic efficacy should be complemented by measures for the recur-
rence of the successfully treated (i.e. occluded) aneurysm. In the absence of 
an agreed definition for recurrence/recanalisation we selected the retreatment 
rate as an endpoint [30]. 
 
Sources 
Results from a systematic literature search (see Section 1.3 and “Literature 
search strategies” of the Appendix) were used to answer the research ques-
tions in the domain “clinical effectiveness”. The selection of relevant docu-
ments was done by two people independently (Figure 1.4-1).  
In terms of study design, only randomised controlled trials with a follow-up 
of ≥6 months were included to assess clinical effectiveness in a population 
with unruptured IA that are amenable to endovascular or surgical treatment. 
To assess clinical effectiveness in a population with unruptured IA not eligi-
ble for standard treatment, all prospective studies with a follow-up ≥6 months 
and with ≥50 patients were included, provided that any of the defined out-
comes were reported. The rationale is that the annual risk of rupture for in-
tracranial aneurysms without treatment is known and the spontaneous oc-
clusion of intracranial aneurysms is an unlikely event. An implicit compari-
son might therefore be meaningful, depending on the magnitude of the ef-
fect and the study population [31]. 
 
Analysis 
No additional data analysis/quantitative synthesis were performed. The in-
ternal validity of the studies was assessed using the 18 criteria checklist for 
single-group studies (Table A2-1).  
 
Synthesis 
The questions were answered in plain text format with reference to GRADE 
evidence tables that are included in Table 6-1. 
 
 
- angiographische 
Endpunkte als 
Surrogatparameter 
- Wiederbehandlungs-
rate 
Quellen: systematische 
Literatursuche 
nur Einschluss von 
prospektiven Studien, 
Follow-up ≥ 6 Monate 
keine quantitative 
Synthese 
Clinical effectiveness 
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4.2 Results 
Included studies 
None of the studies fulfilled the inclusion criteria to answer research ques-
tions related to the primary target population (unruptured intracranial an-
eurysms without further specification). 
From the systematic review, five studies were included [32-36] to address re-
search questions of the second target population (“untreatable” unruptured 
intracranial aneurysms). 
Study characteristics and results of included studies are displayed in Table 
A1-1 and in the evidence profile in Table 6-1. 
All five were prospective, multi-centre, single-group studies that analysed 
mortality, angiographic efficacy and major safety endpoints such as ischemic 
stroke and haemorrhage. All studies had defined inclusion criteria restricting 
the study population to aneurysms with unfavourable characteristics (large, 
wide-necked, fusiform, recurrent after previous treatment, etc.) and all but 
one [34] excluded ruptured aneurysms. Inclusion criteria and cut-off values 
showed some heterogeneity leading to differences between studies with re-
gards to the proportion of large/fusiform/wide-necked aneurysms. Similarly, 
the proportion of patients presenting with symptoms or functional disability 
varied between the studies. 
Clinical follow-up in all studies was up to six months, with the exception of 
[32], which presented clinical follow-up after one year and three years. 
 
Mortality  
D0001 – What is the expected beneficial effect of flow diverters  
on mortality? 
In five prospective single group studies (reporting results from 494 patients 
in total), overall mortality ranged from 0–8% [32-36].  
 
Morbidity 
D0005 – How do flow diverters affect symptoms and risk of rupture 
(severity, frequency) of intracranial aneurysms? 
Three studies reported mRS scores at baseline and follow-up. One study (150 
pts.) indicated no significant overall change in neurologic outcomes based on 
the Wilcoxon signed rank test [36]. An improvement of symptoms was re-
ported by two studies (250 pts.) in 8.4% [32] and 19.6% [35] of the patients; 
the proportion of patients with a worsening of symptoms following the pro-
cedure ranged from 2.7% to 14% [32, 34-36]. 
As a surrogate parameter for a reduced risk of rupture, complete aneurysm 
occlusion was analysed. After six months it ranged between 49% and 85.7% 
as reported by all five studies (502 aneurysms) [32-36]. After one year, aneu-
rysm occlusion ranged between 81% [32] and 86.8% [35]. The occurrence of 
parent artery stenosis >50% ranged between 0% and 16.3% [32-36].  
 
0 Studien zu primärer 
Zielpopulation 
5 Studien zu sekundärer 
Zielpopulation 
alle Studien: prospektiv, 
multi-zentrisch, 
unkontrolliert 
Mortalität: 0–8 % 
verbesserter mRS:  
8,4 bis 19,6 % 
verschlechterter mRS: 
2,7 bis 14 % 
vollständiger 
Aneurysmaverschluss: 
49 bis 85,7 % nach  
6 Monaten 
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D0006 – How do flow diverters affect recurrence of intracranial 
aneurysms? 
Two studies (142 pts.) provided information on the retreatment rate of the 
treated aneurysms (0% after one year of follow-up, [32] and 4.5% after a me-
dian follow-up of six months [34]). 
 
Function 
D0011 – What is the effect of flow diverters on patients’ body functions? 
D0016 – How does the use of flow diverters affect activities of daily living? 
The results on changes in disability/dependence based on the mRS scores are 
described in D0005. 
 
Health-related quality of life 
D0012 – What is the effect of flow diverters on generic  
health-related quality of life? 
D0013 – What is the effect of flow diverters on disease-specific  
quality of life? 
Quality of life was not addressed in any of the five prospective studies. 
 
Patient satisfaction 
D0017 – Was the use of flow diverters worthwhile? 
Patient satisfaction was not addressed in any of the five prospective studies. 
 
Wiederbehandlungsrate 
0 bis 4,5 % nach  
6 Monaten 
keine Ergebnisse zu 
Lebensqualität 
keine Ergebnisse zu 
PatientInnen-
zufriedenheit 
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5 Safety 
5.1 Methods 
Research questions  
Element ID Research question 
Importance 
2 = critical 
1 = optional 
C0008 How safe are flow diverters in comparison to observation only, endovascular 
coiling or surgical clipping? 
2 
C0002 Are the harms related to the dosage or the frequency of applying flow diverters? 2 
C0004 How does the frequency or severity of harms change over time or in different 
settings? 
2 
C0005 What are the susceptible patient groups that are more likely to be harmed 
through the use of flow diverters? 
2 
C0007 Are flow diverters and comparator(s) associated with user-dependent harms? 2 
B0010 What kind of data/records and/or registry are needed to monitor the use of flow 
diverters and the comparator? 
1 
 
As any stent implant, the treatment with flow diverters is associated with the 
risk of thromboembolic complications (with the major consequence being is-
chemic stroke), that can be caused for example by the occlusion of perforator 
vessels or the flow diverter stent itself. This complication can occur peri-pro-
cedurally, as well as in a delayed manner. 
Another reported complication is the rupture of the target aneurysm, leading 
to intracranial haemorrhage. Ruptures are often caused by procedural perfo-
rations; however, delayed aneurysm ruptures and ruptures/bleeding events 
remote from the treated aneurysms have also been reported. Delayed aneu-
rysm rupture has led to a medical device alert issued by Balt Extrusion in-
structing practitioners not to use the Silk flow diverter without coils, owing to 
the potential for patient death [37].  
The following crucial outcomes were thus used as evidence to derive  
a recommendation: 
 Neurological death 
 Haemorrhage (total and early, ≤30d) 
 Ischemic stroke (total and early, ≤30d) 
 New or worsened disability/dependency 
 
Sources 
Results from a systematic literature search (see Section 1.3 and “Literature 
search strategies” of the Appendix) were used to answer the research ques-
tions in the domain “Safety”. The selection of relevant documents was done 
by two people independently (Figure 1.4-1).  
In terms of study design, RCTs with a follow-up ≥6 months and prospective 
non-randomised controlled studies ≥6 months were included. In addition, 
prospective single group studies with a follow-up ≥6 months were included 
if a) ≥200 patients or b) ≥50 patients and the reporting of mortality AND 
further adverse events were included. 
thromboembolische 
Komplikationen 
Ruptur des 
Zielaneurysmas 
entscheidende 
Sicherheitsendpunkte: 
- neurologischer Tod 
- Hämorrhagie 
- ischämischer 
Schlaganfall 
- Pflegebedürftigkeit 
Quellen: systematische 
Literatursuche 
nur Einschluss von 
prospektiven Studien, 
Follow-up ≥ 6 Monate 
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Analysis 
The sources were sufficient to answer the questions. We did not perform ad-
ditional data analysis. Quality was assessed using the 18 criteria checklist for 
single-group studies (Table A2-1). 
 
Synthesis 
The questions were answered in plain text format with reference to GRADE 
evidence tables that are included in Table 6-1. 
 
 
5.2 Results 
Included studies 
None of the studies fulfilled the inclusion criteria to answer research ques-
tions related to the primary target population (unruptured intracranial an-
eurysms without specification). 
From the systematic review, five studies were included [32-36] to address re-
search questions regarding the second target population (“untreatable” un-
ruptured intracranial aneurysms). 
Study characteristics and results of included studies are displayed in Table 
A1-1 and in the evidence profile in Table 6-1. 
In all of the studies, the treatment with flow diverter was accompanied by a 
dual antiplatelet regimen and occasionally an adjuvant treatment with coils.  
 
Patient safety 
C0008 – How safe are flow diverters in comparison to observation only, 
endovascular coiling or surgical clipping? 
Neurologic death was reported in all five studies (511 pts.) ranging from 0% 
to 3.0% [32-36]. Haemorrhages were reported in five studies (494 pts.) and oc-
curred in a range of 0% to 6.2% [32-36]; two cases of late haemorrhage (≥30d) 
were reported in two studies [32, 34]. Ischemic strokes were reported in 5 
studies (494 pts.), within a range of 0% to 3.7%, with no cases reported later 
than 30 days [32-36]. The proportion of patients with worsening symptoms 
following the procedure was reported in four studies (450 pts.) and ranged 
from 2.7% to 14% [32, 34-36]. 
 
C0002 – Are the harms related to the dosage or the frequency  
of applying flow diverters? 
No evidence was identified to answer the research question. 
 
C0004 – How does the frequency or severity of harms change over  
time or in different settings? 
No evidence was identified to answer the research question. 
 
keine quantitative 
Synthese 
0 Studien zu primärer 
Zielpopulation 
5 Studien zu sekundärer 
Zielpopulation 
neurologischer Tod:  
0 bis 3 % 
Hämmorrhagie:  
0 bis 6,2 % 
ischämischer 
Schlaganfall: 0 bis 3,7 % 
verschlechterter mRS: 
2,7 bis 14 % 
Safety 
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C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of flow diverters? 
No evidence was identified to analyse the susceptibility of subgroups of pa-
tients (aneurysms) to specific complications. 
 
C0007 – Are flow diverters and comparator(s) associated with  
user-dependent harms? 
No evidence was identified to answer the research question. 
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6 Quality of evidence 
The strength of evidence was rated according to GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) Schema [38] for each 
endpoint individually. Each study was rated by two independent researchers. 
In case of disagreement, a third researcher was involved to solve the differ-
ence. A more detailed list of criteria applied can be found in the recommen-
dation of the GRADE Working Group [38].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close to that of 
the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
 
Primary target population:  
No evidence is available for the effectiveness and safety of the endovascular 
embolization of intracranial aneurysms with flow diverters for the treatment 
of unruptured intracranial aneurysms without morphological specification. 
 
Secondary target population: 
Overall, the strength of evidence for the effectiveness and safety of the endo-
vascular embolization of large, giant, fusiform or wide-necked intracranial 
aneurysms with flow diverters in indirect comparison to no treatment is very 
low. Moderate evidence is available for the efficacy of flow diverters to oc-
clude large, giant, fusiform or wide-necked aneurysms.  
For comparison with no treatment, endovascular coiling or surgical clipping 
no direct evidence is available.  
 
 
Qualität der Evidenz 
nach GRADE 
primäre Zielpopulation: 
keine Evidenz 
sekundäre 
Zielpopulation:  
- Nutzen und Sicherheit 
im indirekten Vergleich 
zu Beobachtung:  
sehr niedrige Evidenz 
- wirksamer 
Aneurysmaverschluss: 
moderat 
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Table 6-1: Evidence profile: efficacy and safety of flow diverters in intracranial aneurysms 
No of studies/patients Study design Estimate of effect Study limitations Inconsistency Indirectness 
Other modifying 
factors 
Strength  
of evidence 
Efficacy 
Overall mortality (6mo) 
5/494 pts. Prospective case series Range 0–8% -1 -1 -12 0 Very low 
Retreatment rate (1y) 
2/142 pts. Prospective case series 0–4.5% 0 0 0 0 Very low 
Angiographic efficacy (Total occlusion) 
5/502 an. (6mo) 
2/166 an. (1y) 
Prospective case series Range 49–85.7% (6mo) 
Range 81–86.8% (1y) 
-1 
0 
-1 
0 
-12 
0 
0 
+23 
Very low 
Moderate 
Parent artery stenosis ≥50% 
5/489 pts./an. Prospective case series Range 0–16.3% -1 -1 -12 0 Very low 
Function/Disability, dependence (% improved) 
2/250 pts. Prospective case series Range 8.4–19.6% 0 0 -12 0 Very low 
Safety 
Neurological death 
5/511 pts. (6mo FU) Prospective single-group studies Range 0–2.8% -1 0 -12 0 Very low 
1/134 pts. (1y FU) Prospective single-group studies 2.2%  0 0 0 0 Very low 
Haemorrhage  
5/494 pts. Prospective single-group studies Range 0–6.2% -1 0 -12 0 Very low 
Haemorrhage ≥30d 
4/387 pts. Prospective single-group studies Range 0–2% -1 0 0 0 Very low 
Ischemic stroke 
5/494 pts. Prospective single-group studies Range 0–3.7% -1 0 -12 0 Very low 
Ischemic stroke ≥30d 
4/387 pts. Prospective single-group studies 0% -1 0 0 0 Very low 
Function/Disability, dependence (% worsened) 
4/450 Prospective single-group studies Range 2.7–14% -1 0 -12 0 Very low 
mo = months, an = aneurysms, pts = patients, y = year, FU = Follow-Up 
Nomenclature for GRADE Table:  
Limitations: 0: no limitations; no serious limitations; -1: serious limitations  
Inconsistency: NA: not applicable (only one trial); 0: no important inconsistency; -1: important inconsistency  
Indirectness: 0: direct, no uncertainty; -1: some uncertainty; -2 major uncertainty  
Other modifying factors: publication bias likely (-1); imprecise data (-1); strong or very strong association (+1 or +2); dose-response gradient (+1); Plausible confounding (+1)  
                                                             
2 Follow-up too short 
3 Large effect in comparison to no treatment 
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7 Discussion 
The efficacy and safety of flow diverters in the treatment of unruptured IA 
has already extensively been reviewed in previous systematic reviews [25, 39-
44], including the many retrospective case series available on the topic (Table 
7-1). For this assessment, therefore, we have restricted our analysis on pro-
spective studies as the best available evidence, of which we could identify five. 
Table 7-1: Overview of results from systematic reviews and meta-analyses on flow diverters 
 
Number of 
included 
studies 
(patients) 
Procedure-
related 
Mortality 
Procedure-related 
Morbidity Haemorrhage 
Ischemic 
stroke 
Aneurysmal 
occlusion rate 
Murthy 
2014b [44] 
13 (905)6 2.3%  
(95% CI,  
1.3–3.3%) 
Early: 5.7%  
(95% CI, 4.2–7.2%) 
Late: 1.9%  
(95% CI, 1–2.8%) 
ICH: 1.1%  
(95% CI, 0.4–1.8%) 
SAH: 2.3%  
(95% CI, 1.3–3.3%). 
1.9%  
(95% CI,  
1–2.8%) 
79.7%  
(95% CI,  
76.8–82.6%) 
Murthy 
2014a [43] 
8 (285)4 4.9%  
(95% CI,  
2.4–7.4%) 
Early: 12.5%  
(95% CI, 8.7–16.3%) 
Late: 9.9%  
(95% CI, 6.4–13.4%) 
ICH: 1.4%  
(95% CI, 0.04–2.8%) 
Late SAH: 3.5% 
(95% CI, 1.4–5.6%) 
7.7%  
(95% CI,  
4.6–10.8%) 
81.8%  
(95% CI,  
77.1–86.5%) 
Brinjikji 
2013 [40] 
29 (1,451) 4%  
(95% CI,  
3–6%) 
5%  
(95% CI, 4–7%) 
SAH: 3%  
(95% CI, 2–4%). 
6%  
(95% CI,  
4–9%) 
76%  
(95% CI,  
70–81% 
Arrese 
2013 [39] 
15 (897) Early: 2.8% 
(95% CI,  
1.7–3.8%) 
Late: 1.3% 
(95% CI,  
0.2–2.3%) 
Early: 7.3%  
(95% CI, 5.7–9%) 
Late: 2.6%  
(95% CI, 1.1–4%) 
Early  
Haemorrhage: 0.9% 
(95% CI, 0.2–1.6%) 
Early: 3.6% 
(95% CI,  
2.3–4.9%) 
76.2%  
(95% CI,  
72.1–80.2%) 
Murthy 
2013a [42] 
13 (796)6 2.4% (95% CI, 
1.3–3.5%). 
Early: 2–22% 
Late: 0–13% 
Haemorrhage: 1.6% 
(95% CI, NR) 
1.4%  
(95% CI, 
NR) 
85.5%  
(95% CI,  
82.7–88.4%) 
Naggara 
2012 [25] 
6 (104)5 Unfavourable outcomes incl. death 
11.5% (99% CI, 4.9–24.6%) 
NR NR NR 
Leung 
2012 [41] 
10 (414)6 2.2%  
(95% CI, NR) 
Overall Morbidity: 
10.3% (95% CI, NR) 
NR NR NR 
CI = confidence interval, ICH = intracranial haemorrhage, SAH = subarachnoid haemorrhage, NR = not reported 
 
Overall, the results on mortality, haemorrhage, ischemic stroke and aneurys-
mal occlusion from the systematic reviews are comparable to the results from 
our assessment.  
None of the five studies in our review included a control group, so conclusions 
on relative effectiveness can only be drawn from indirect comparisons. 
Here, the studies provide moderate evidence that flow diverters may lead to 
high rates (>80%) of complete occlusion of large, giant, fusiform or wide-
necked aneurysms after one year.  
                                                             
4 Silk Flow Diverter only 
5 Subgroup of studies on flow diverters 
6 Pipeline Embolization Device only 
Zusammenfassung 
bestehender 
systematischer Reviews 
nur unkontrollierte 
Studien: indirekter 
Vergleich 
 
moderate Evidenz zu 
hohen Verschlussraten 
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The relevance of this outcome to the clinical benefit of the patients is unclear. 
The purpose of the treatment of unruptured IA is the sustainable prevention 
of rupture, SAH and ensuing disability or death. Only two studies provided 
data after a follow-up of one year. The sustainability of the occlusion has not 
been addressed; the provided evidence on recurrence of the aneurysms is in-
sufficient. Moreover, the rating of the grade of occlusion is subjective and 
prone to bias.  
Retreatment is an issue with endovascular treatments in comparison to sur-
gical clipping and has been estimated to occur in ~9% of aneurysms treated 
by endovascular coiling [25]. Two studies in the present assessment addressed 
this issue and reported retreatment rates of 0% and 4.5% respectively. The 
first estimate, however, was determined with a follow-up in only 75/143 pa-
tients.  
As demonstrated in the ISUIA study, the risk of rupture varies in depend-
ence of the size, the location of the aneurysm and the history of SAH in the 
patient (Table 3.2-1). Heterogeneity in the results may be caused by hetero-
geneous study populations, including different proportions of high-risk an-
eurysms, which make indirect comparisons challenging. A systematic review 
of studies analysing the risk of rupture in unruptured IA found a range of 0 
to 8.7% SAH per person-year [14]. In the studies identified in this assessment, 
the range of haemorrhage was 0 to 6.2%. Thus, no beneficial effect of flow 
diverters on the risk of rupture in comparison to no treatment can be deduced 
from the present evidence base.  
The indirect comparison with the natural course of disease is only valid un-
der the assumption that flow diverters are used for the treatment of aneurysm 
for which no alternative treatment is available. In practice, however, there is 
no agreed definition of an “untreatable” aneurysm, as underlined by the het-
erogeneous inclusion criteria defined in the studies. In fact, the notion of “un-
treatable” aneurysm may be true only in rare cases with a combination of un-
favourable patient characteristics and aneurysm characteristics. In most pa-
tients, however, a more conventional, conservative, or validated approach such 
as coiling, parent vessel occlusion, or surgical clipping likely exists. Mortality 
and morbidity rates for endovascular coiling are estimated at 1.7% and 7.7% 
respectively in unruptured aneurysms, with the two most frequent complica-
tions being thromboembolic complications and intraoperative rupture [45]. 
Overall mortality and morbidity for surgical treatment was estimated at 12.6% 
[10]. Due to the small differences and the variability in dependence of the 
aneurysm type, location and history, the trade-off of procedural risks with 
long-term beneficial outcomes in comparison to standard treatment needs to 
be established in randomised clinical trials.  
Five RCTs using flow diversion as an intervention are currently registered 
(Table A3-1). With the exception of the MARCO POLO trial, all have defined 
inclusion criteria based on some notion of “difficult” aneurysms (e.g. large 
or wide-necked). Notably, the FIAT trial is expected to provide efficacy and 
safety outcomes of flow diversion versus standard treatment following the 
study primary completion date in April 2016. 
 
 
Beständigkeit des 
Verschlusses aufgrund 
kurzer Follow-ups 
unklar 
Wiederbehandlung in  
0 bis 4,5 % 
keine Evidenz zur 
Verringerung des 
Rupturrisikos im 
indirekten Vergleich mit 
unbehandelten IA  
Vergleich mit 
Rupturrisiko ohne 
Behandlung nur in 
wenigen Fällen zulässig  
keine klare Definition 
„unbehandelbarer“ IA, 
meist Behandlungs-
optionen vorhanden 
 
Abwägung von 
Behandlungsrisiko  
und -nutzen nur über 
RCTs möglich 
5 registrierte RCTs  
FIAT Studie: 
Wirksamkeits und 
Sicherheitsdaten nach 
Studienende April 2016 
zu erwarten 
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8 Recommendation 
In Table 8-1 the scheme for recommendations is displayed and the according 
choice is highlighted. 
Table 8-1: Evidence-based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
X The inclusion in the catalogue of benefits is currently not recommended. 
 The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning:  
There is moderate evidence that treatment with flow diverters leads to aneu-
rysm occlusion in a large percentage of treated aneurysms.  
The current evidence is, however, not sufficient to prove, that the assessed 
technology of endovascular embolization with flow diverters is more effective 
and safe with regards to clinical outcomes than no treatment, endovascular 
coiling or surgical clipping.  
The re-evaluation is recommended in 2017, provided that data from random-
ised controlled trials will be available at that time. 
 
 
 
 
moderate Evidenz zu 
Aneurysmaverschluss 
ungenügende Evidenz 
hinsichtlich 
Überlegenheit der FD  
im Vergleich zu 
Standardbehandlung 
 
Re-evaluierung 2017 
oder sobald RCT Daten 
verfügbar 
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Appendix 
Evidence tables of individual studies included for clinical effectiveness and safety 
Table A1-1: Flow diverters: Results from observational studies 
Author, year, Wakhloo (2014) Becske (2013) Yu (2012) McAuliffe (2012) Byrne (2010) 
Country US, AR, NL, DE, FR, HU, JP, 
IE, CL, IT, UK 
US, HU, TK HK AU worldwide (details NR) 
Sponsor NR Chestnut Medical and ev3 
(Covidien) 
NR ev3 Balt Extrusion 
Intervention/Product Surpass Flow Diverter Pipeline Embolization Device Pipeline Embolization Device Pipeline Embolization Device SILK Flow Diverter 
Concomitant 
medication and therapy 
Dual antiplatelet therapy 
Coil treatment (36 aneurysms) 
Dual antiplatelet therapy 
Coil treatment (1 aneurysm) 
Dual antiplatelet therapy 
Coil treatment (9 aneurysms) 
Dual antiplatelet therapy 
Coil treatment (6 patients) 
Dual antiplatelet therapy 
Coil treatment (10 patients) 
Comparator - - - - - 
Study design Prospective, multi-centre, 
single- group study 
Prospective, multi-centre, 
single-group study (PUFs) 
Prospective, multi-centre, 
single-group study 
Prospective multi-centre, 
single-group study 
Prospective, multi-centre, 
single-group study 
Number of patients 165 108 143 54 70 
Number of aneurysms 190 108 (+2 qualifying contralateral 
aneurysms in 2 patients) 
178 57 70 
Inclusion criteria Aneurysms of any size 
located in the anterior or 
posterior circulation with 
neck diameter >4mm or 
dome-to-neck ratio ≤2 
Presence of an aneurysm 
arising from the internal 
carotid artery (petrous 
through the superior 
hypophyseal segments) with 
aneurysm diameter ≥ 10mm 
and neck diameter ≥ 4 mm 
a) Saccular or fusiform 
aneurysms;  
b) Untreated unruptured 
aneurysms or recurrent 
aneurysms after previous 
treatment;  
c) Aneurysm diameter 
≥10mm or dome-to-neck 
ratio ≤1 or neck diameter 
≥4mm or multiple aneurysms 
within a 1cm distance;  
d) Parent vessel diameter 
2.5-5mm 
Aneurysms with neck 
diameter >4mm or dome-to-
neck ratio <1.6 or aneurysm 
diameter >10mm or fusiform 
or failed treatment 
"Patients were selected for 
treatment locally on the basis 
that the target aneurysm 
was unsuitable for 
conventional treatment." 
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Author, year, Wakhloo (2014) Becske (2013) Yu (2012) McAuliffe (2012) Byrne (2010) 
Exclusion criteria SAH associated with 
ruptured aneurysm within 
previous 30d; 
contraindication or non-
responders to dual antiplatelet 
therapy, non-treated brain 
arteriovenous malformation 
SAH within previous 60d, 
any intracranial haemorrhage 
or major surgery within 
previous 42d, history of 
bleeding disorder or low 
platelet count, previously 
placed stent at the target 
aneurysm, contraindication 
to CT or MRI, allergy to 
platinum/cobalt/chromium 
alloys, active infection, major 
stenosis of ipsilateral carotid 
artery + indwelling stent 
previously placed across the 
neck of target IA 
a) Dissecting aneurysm;  
b) SAH within previous 50d;  
c) Intracranial arteriovenous 
malformation;  
d) Parent artery stenosis of 
≥50% 
Acute SAH Any contraindication to 
antiplatelet drugs, 
pregnancy, breast feeding, 
and aneurysms considered 
treatable with coils alone 
Patient characteristics 
Mean age of patients (y)  57.1 (range 28–82) 57± 11.3 (range 30.2–75.1) 54.9±11.4 (range 27–82) 55.7 (range 30–83) Not collected 
Sex 72.4% female 88.9% female 74.8% female 81.5% female Not collected 
Risk factors NR 55.6% hypertension, 57.4% 
smoker, history of SAH 7.4% 
NR NR NR 
Clinical presentation Asymptomatic or chronic 
headache: 31.8%, 
cranial nerve palsy/mass 
effect: 18.6% 
71/108 (65.7%) presented 
with neuropathy of cranial 
nerves 2-6 
Asymptomatic: 81.1%, 
headache: 9.1%, 
cranial nerve palsy: 9.8% 
Asymptomatic: 70.4%,  
cranial nerve palsy/mass 
effect: 29.6% 
Asymptomatic: 43%,  
symptomatic with no or mild 
disability: 44%, moderate or 
significant disability: 13%. 
Ruptured aneurysms:  
10 (14.3%) 
Baseline functional score mRS: NR mRS≤ 1 in 87.1% mRS ≤ 1 in 96.5% mRS: NR mRS ≤ 1 in 70% 
Aneurysm characteristics 
Type 125 wide-neck saccular (67.2%), 
54 fusiform/dissecting 
(29.0%), 7 blister-like (3.8%) 
NR 173 saccular aneurysms 
(97.2%); 5 fusiform (2.8%) 
46 saccular/berry (80.7%), 
11 fusiform (19.3%) 
44 saccular (62.9%),  
26 fusiform (37.1%) 
Recurrent/ 
prior failed treatment  
Recurrent aneurysms in  
24% of the patients 
8 recurrent aneurysms 
(7.4%) 
34 recurrent aneurysms 
(19.1%) 
Recurrent aneurysms in 
29.6% of the patients 
NR 
Location 27 posterior circulation 
(14.5%) 
0 posterior circulation (0%) 6 posterior circulation 
(3.4%) 
11 posterior circulation 
(19.3%) 
26 posterior circulation 
(37.1%) 
Measurements Mean size 10.4 ± 0.7mm, 
mean neck diameter 6.0 ± 
0.4mm, mean dome-to-neck 
ratio 1.6 ± 0.08% 
Mean size 18.2± 6.4mm, 
mean neck diameter  
8.8 ± 4.3mm 
 Mean size 13.1mm  
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Author, year, Wakhloo (2014) Becske (2013) Yu (2012) McAuliffe (2012) Byrne (2010) 
Size ≥ 10mm: 69 (37.1%) Size ≥ 10mm: 107 (99.1%); 
Neck ≥ 6mm: 85 (78.7%) 
Size ≥10mm: 33 (18.5%);  
Neck ≥4mm: 96 (53.9%) 
Size ≥ 10mm: 39 (68.4%); 
Dome-to-neck<1.6 or 
neck>4mm: 57 (100%) 
Size ≥ 10mm: 52 (74.3%);  
Neck ≥ 4mm: 38 (73.1%)7 
Follow-up Clinical and angiography: 
Median, 6mo  
(range 1-38mo) 
Clinical: 6mo 
Angiography: 6mo and 1y 
Clinical and angiography: 
Median, 18.2 mo (range 3-
39.2mo) 
Clinical: 1y, 3y 
Angiography: 6mo, 1y, 18mo 
Clinical: 6mo 
Angiography: 6mo 
Clinical and angiography: 
Median, 119d (range 9-528d) 
Loss to follow-up, n (%)  Clinical: 15/165 (9.1%) (4 
failed treatment, 11 refused) 
Angiography: 32/190 
(16.8%) (4 failed treatment) 
Clinical @6mo: 5/108 (4.6%) 
(1 failed treatment,  
4 FU by phone) 
Angiography @6mo: 11/108 
(10.2%) (1 failed treatment, 
3 excluded, 3 dead, 4 refused) 
Angiography @1y 19/108 
(17.6%) (11 see above, 7 NR) 
Clinical @1y: 9/143 (6.3%)  
Clinical @3y: 95/143 (66.4%) 
– data not extracted 
Angiography @6mo: 
 38/178 (21.3%) 
Angiography @1y:  
103/178 (57.9%) 
Clinical @6mo: 1/54 (1.9%) 
Angiography @6mo:  
1/57 (1.8%) 
Clinical: 20/70 (29%)  
(3 failed treatment) 
Angiography: 21/70 (30%)  
(3 failed treatment) 
Outcomes 
Efficacy 
Overall mortality, n (%) 7/150 (4.7%)8 3/107 (2.8%) (6mo FU) 2/134 (1.5%) (6mo FU) 
3/134 (2.2%) (1y FU) 
0/53 (0%) (6mo FU) 4/50 (8%)8 
Retreatment rate, n (%) NR NR 0/75 (0%) aneurysms (1y FU) NR 3/67 (4.5%)8 
Angiographic efficacy 
(Total occlusion), n (%) 
118/158 (74.7%) aneurysms8 78/99 (78.8%) aneurysms 
(6mo FU) 
79/91 (86.8%) aneurysms 
(1y FU) 
78/140 (55.7%) aneurysms 
(6mo FU) 
61/75 (81%) aneurysms  
(1y FU) 
48/56 (85.7%) aneurysms 
(6mo FU)9 
24/49 (49%) aneurysms8 
Parent artery stenosis  
≥ 50% 
8/150 (5.3%)8 2/97 (2.0%) (6mo FU) 0/140 (0%) aneurysms 2/53 (3.5%) 8/49 (16.3%)10,8 
                                                             
  7 Measured for 43 saccular aneurysms 
  8 No fixed follow-up time point 
  9 Occlusion grade not specified 
10 Parent artery occlusion or “severe” degree of arterial narrowing 
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Author, year, Wakhloo (2014) Becske (2013) Yu (2012) McAuliffe (2012) Byrne (2010) 
Function/Disability, 
dependence (mRS) 
Wilcoxon matched pairs 
signed rank test indicates no 
significant change in 
neurologic outcomes (P=.55); 
worse in 4/150 (2.7%)8 
Improved in 21/107; 
unchanged 70/107; worse 
10/107 (9.3%), unavailable in 
6/107 (6mo FU) 
Improved in 12/143; 
unchanged in 119/143; worse 
in 12/143 (8.4%) (30d FU) 
NR Worse in 7/50 (14%)11,8 
Safety 
Neurologic death 4/150 (2.7%)8 3/107 (2.8%) (6mo FU) 2/134 (1.5%) (6mo FU) 
3/134 (2.2%) (1y FU) 
0/53 (0%) (6mo FU) 2/67 (3.0%)8 
Haemorrhage  10/150 (6.2%) 6/107 (5.6%) 5/134 (3.7%)12 (1y FU) 0/53 (0%) 1/50 (2%) 
Haemorrhage ≥ 30d 0/150 (0%) NR 1/134 (0.7%)12 (1y FU) 0/53 (0%) 1/50 (2%) 
Ischemic stroke 3.7%12 4/107 (3.7%) 1/134 (0.7%)12 (1y FU) 0/53 (0%) 1/50 (2%) 
Ischemic stroke ≥ 30d 0/150 (0%)12 NR 0/134 (0%)12 (1y FU) 0/53 (0%) 0/50 (0%) 
Serious adverse events NR 44 events 12/134 (9.0%)13 (1y FU) 5/53 (9.4%)14 12/50 (24%) 
d = day(s); FU = Follow-Up; mo = months; IS = Ischemic Stroke; mRS = modified Rankin Scale; NR = not reported; SAH = Subarachnoid Haemorrhage;  
TIA = Transient Ischemic Attack; y = year(s) 
  
                                                             
11 Baseline measured with Glasgow Coma Score, follow-up scores NR 
12 Only major stroke reported, n NR 
13 Only neurological complications reported 
14 Only TIA, stroke, SAH or mass effect documented 
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Risk of bias tables 
The internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the dif-
ferences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found in the Internal Manual of the 
LBI-HTA [46] and in the Guidelines of EUnetHTA [47].  
Table A2-1: Risk of bias – Study level 
18 criteria checklist:  
critical appraisal single-group studies 
Wakhloo 
(2014) 
Becske 
(2013) 
Yu  
(2012) 
McAuliffe 
(2012) 
Byrne 
(2010) 
Study objective 
Is the hypothesis/aim/objective of the study stated clearly in the abstract, introduction, or methods section? Yes Yes Yes Yes Yes 
Study population 
Are the characteristics of the participants included in the study described? Yes Yes Yes Yes Yes 
Were the cases collected in more than one centre? Yes Yes Yes Yes Yes 
Are the eligibility criteria (inclusion and exclusion criteria) for entry into the study explicit and appropriate? Yes Yes Yes Yes No 
Were participants recruited consecutively? Yes Yes Yes Yes No 
Did participants enter the study at similar point in the disease? Yes Yes Yes Yes No15 
Intervention and co-intervention 
Was the intervention clearly described in the study? Yes Yes Yes Yes Yes 
Were additional interventions (co-interventions) clearly reported in the study? Yes Yes Yes Yes Yes 
Are the outcome measures clearly defined in the introduction or methods section? No Yes Yes No No 
Were relevant outcomes appropriately measured with objective and/or subjective methods? No16 Yes Yes Unclear No16 
Were outcomes measured before and after intervention? Yes Yes Yes Yes Yes 
Statistical analysis 
Were the statistical tests used to assess the relevant outcomes appropriate? Yes18 Yes17,18 Yes18 Yes18 Yes18 
                                                             
15 Study population included patients with ruptured aneurysms. 
16 Outcomes were measured at variable time-points (no minimum follow-up) 
17 Statistical effectiveness analysis versus fixed threshold was not considered in this report 
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18 criteria checklist:  
critical appraisal single-group studies 
Wakhloo 
(2014) 
Becske 
(2013) 
Yu  
(2012) 
McAuliffe 
(2012) 
Byrne 
(2010) 
Results and conclusions 
Was the length of follow-up reported? Yes Yes Yes Yes Yes 
Was the loss to follow-up reported? Yes Yes Yes Yes Yes 
Does the study provide estimates of the random variability in the data analysis of relevant outcomes?18 No Yes Yes No No 
Are adverse events reported? Yes Yes Yes Yes Yes 
Are the conclusions of the study supported by results? Yes Yes No19 Yes Yes 
Competing interests and sources of support 
Are both competing interests and sources of support for the study reported? No Yes Yes Yes Yes 
Overall risk of bias at study level High Low Low High High 
Source: [48] 
 
                                                             
18 Data reported are absolute counts. 
19 Authors recommend considering PED “a first choice for treatment of unruptured IA” 
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Applicability table 
Table A3-1: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population Study populations represent a wide spectrum of aneurysms in terms of size, morphology, location 
and stage of disease. The inclusion criteria do not reflect truly “untreatable” aneurysms, but rather 
“challenging” aneurysms. 
Intervention The studies include three marketed products (Surpass, Silk and Pipeline). All had concomitant anti-
platelet therapy. Applicability might be limited due to some studies using adjuvant endosaccular 
coiling and others not. 
Comparators None of the studies included a comparison group.  
Outcomes Outcomes most frequently reported are aneurysm occlusion, mortality, neurological death and stroke. 
Only two studies presented follow-up >6 months. Thus, long-term stability and preventive effect of 
aneurysm rupture may not be assessed. 
Setting All of the studies included were multi-centre studies, with clinical centres based in Europe, Australia, 
South America and Asia. Therefore, it can be assumed that the results reflect a wide spectrum of 
clinical routines both with regard to patient selection and treatment modalities and, therefore, that 
results are transferable to the Austrian setting. The surgeon’s technical expertise likely determines 
the risk of local side effects. If introduced as a new treatment method in European hospitals, the 
treatment with flow diverters will certainly be accompanied by a learning curve.  
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List of ongoing randomised controlled trials 
Table A4-1: List of ongoing randomised controlled trials of flow diverters 
Identifier/Trial name Patient population Intervention Comparison Outcome 
Primary 
completion date Sponsor 
NCT01762137 
LARGE aneurysm randomized 
trial: flow diversion versus 
traditional endovascular coiling 
therapy (LARGE) 
Patients aged 21–75 internal carotid artery 
aneurysms (petrous, cavernous, and 
paraophthalmic) with neck and fundus 
morphologies amenable to either traditional 
endovascular treatments using coils or 
reconstruction with the flow diversion. 
Aneurysm neck ≥4 mm. Fundus ≥10 mm 
Flow diversion Endovascular coil 
embolization 
Non-inferiority 
with regard to 
efficacy and 
safety at 180 
days after 
procedure. 
April 2018 Medical 
University of 
South 
Carolina, US 
NCT01349582 
Flow diversion in intracranial 
aneurysm treatment (FIAT) trial 
Any patient with a “difficult” intracranial 
aneurysm in whom flow diversion is 
considered an appropriate, if not the best 
yet unproved therapeutic option by the 
participating clinician 
Flow diversion Standard treatment of 
any of the following:  
(1) conservative 
management, (2) coil 
embolization with or 
without high porosity 
stent, (3) parent vessel 
occlusion, or (4) surgical 
clipping 
Efficacy and 
safety 
April 2016 Centre 
hospitalier de 
l'Université de 
Montréal, CA 
NCT01811134 
Endovascular treatment of 
intracranial aneurysm with 
pipeline versus coils with or 
without stents (EVIDENCE) trial 
Unruptured saccular intracranial 
aneurysms >7 mm 
Pipeline 
embolization 
device 
Endovascular coil 
embolization with or 
without balloon 
remodelling, with or 
without stent assistance 
Efficacy Nov 2015 Hospices Civils 
de Lyon, FR 
NCT01084681 
Multi-centre randomised trial on 
selective endovascular aneurysm 
occlusion with coils versus parent 
vessel reconstruction using the 
SILK flow diverter (MARCO 
POLO) 
Patients with at least one documented 
untreated, unruptured intracranial 
aneurysm suitable for occlusion with an 
intracranial device 
SILK flow 
diverter without 
coils 
Endovascular coil 
embolization with or 
without balloon 
remodelling or stent 
assistance 
Efficacy and 
safety 
Oct 2012 Balt 
International 
ChiCTR-TRC-13003127 
Parent artery reconstruction for 
large or giant cerebral aneurysms 
using Tubridge flow diverter 
Patients with unruptured carotid or 
vertebral artery aneurysms (including 
saccular or recanalized aneurysms. Neck 
≥4mm, size ≥10mm 
Tubridge flow 
diverter +/- bare 
coils 
Enterprise stent 
combined with bare coils 
Efficacy and 
safety 
NR MicroPort 
NeuroTech 
(Shanghai) 
Co., Ltd. 
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Literature search strategies 
Search strategy for Cochrane 
Search Name: Flow Diverters for Intracranial Aneurysm 
Last Saved: 12/12/2014 15:21:33.840 
ID Search 
#1 MeSH descriptor: [Intracranial Aneurysm] explode all trees 
#2 intracranial aneurysm* (Word variations have been searched) 
#3 intra-cranial aneurysm* (Word variations have been searched) 
#4 #1 or #2 or #3  
#5 flow diverter* (Word variations have been searched) 
#6 flow diversion* (Word variations have been searched) 
#7 flow-diverting (Word variations have been searched) 
#8 pipeline embolization device* (Word variations have been searched) 
#9 silk near diver* (Word variations have been searched) 
#10 surpass near diver* (Word variations have been searched) 
#11 endoluminal reconstruction* (Word variations have been searched) 
#12 flow redirection endoluminal device* (Word variations have been searched) 
#13 FRED (Word variations have been searched) 
#14 MeSH descriptor: [Therapeutic Occlusion] this term only 
#15 aneurysm* next occlusion* (Word variations have been searched) 
#16 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #13 or #14 or #15  
#17 #4 and #16 
40 Hits 
12.12.2014 
 
Search strategy for CRD 
Search Name: Flow Diverters (MELs 2015) AK 
1 (flow diver*) 
2 (pipeline emboli*ation device*) 
3 (silk NEAR diver*) 
4 (surpass NEAR diver*) 
5 (endoluminal reconstruction*) 
6 (aneurysm occlusion*) 
7 (flow redirection endoluminal device*) 
8 #1 OR #2 OR #3 OR #6 
10 Hits 
12.12.2014 
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Search strategy for EMBASE 
Query Results  
'clinical article'/de OR 'clinical study'/de OR 'clinical trial'/de OR 'comparative study'/de OR 'controlled clinical trial'/de OR 
'controlled study'/de OR 'feasibility study'/de OR 'intermethod comparison'/de OR 'major clinical study'/de OR 'multicenter 
study'/de OR 'prospective study'/de OR 'randomized controlled trial (topic)'/de OR 'retrospective study'/de OR 
'systematic review'/de AND ('intracranial aneurysm'/mj OR 'intracranial aneurysm' OR 'intracranial aneurysms' OR 
'intra-cranial aneurysm' OR 'intra-cranial aneurysms') AND ('flow diverter' OR 'flow diverters' OR 'flow diversion' OR 
'flow diversions' OR 'flow-diverting' OR 'pipeline embolization device'/exp OR 'pipeline embolisation device' OR 'pipeline 
embolisation devices' OR 'pipeline embolization devices' OR 'pipeline embolization device' OR silk:dn OR surpass:dn OR 
'endoluminal reconstruction' OR 'endoluminal reconstructions' OR 'aneurysm occlusion' OR 'aneurysm occlusions' OR 
'flow redirection endoluminal device' OR fred:dn OR 'therapeutic occlusion' OR 'therapeutic occlusions') AND 'human'/de 
338 Hits 
12 .12.2014 
 
Search strategy for OVID Medline 
Database: Ovid MEDLINE(R) <1946 to November Week 3 2014>, Ovid MEDLINE(R) In-Process & 
Other Non-Indexed Citations <December 10, 2014>, Ovid MEDLINE(R) Daily Update <November 19, 
2014>, Ovid OLDMEDLINE(R) <1946 to 1965> 
Search Strategy: 
1 exp Intracranial Aneurysm/(22204) 
2 intracranial aneurysm*.mp. (23741) 
3 1 or 2 (23741) 
4 flow diverter*.mp. (267) 
5 flow diversion*.mp. (289) 
6 flow-diverting.mp. (149) 
7 pipeline emboli#ation device*.mp. (190) 
8 (silk adj5 diver*).mp. (64) 
9 (surpass adj5 diver*).mp. (9) 
10 endoluminal reconstruction*.mp. (22) 
11 aneurysm occlusion*.mp. (469) 
12 flow redirection endoluminal device*.mp. (2) 
13 FRED.mp. (747) 
14 *Therapeutic Occlusion/(49) 
15 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 (1871) 
16 3 and 15 (675) 
17 exp Clinical Trial/or double-blind method/or (clinical trial* or randomized controlled trial or 
multicenter study).pt. or exp Clinical Trials as Topic/or ((randomi?ed adj7 trial*) or (controlled 
adj3 trial*) or (clinical adj2 trial*) or ((single or doubl* or tripl* or treb*) and (blind* or 
mask*))).ti,ab. (1237296) 
18 ((systematic adj3 literature) or systematic review* or meta-analy* or metaanaly* or "research 
synthesis" or ((information or data) adj3 synthesis) or (data adj2 extract*)).ti,ab. or (cinahl or 
(cochrane adj3 trial*) or embase or medline or psyclit or (psycinfo not "psycinfo database") or 
pubmed or scopus or "sociological abstracts" or "web of science").ab. or "cochrane database of 
systematic reviews".jn. or ((review adj5 (rationale or evidence)).ti,ab. and review.pt.) or meta-
analysis as topic/or Meta-Analysis.pt. (216677) 
19 17 or 18 (1379293) 
20 16 and 19 (121) 
21 remove duplicates from 20 (117) 
117 Hits 
11.12.2014 
